Dublin, Oct. 08, 2020 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredient (API) Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), by Product (Vaccines, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology, CVD) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period.
Growth in the active pharmaceutical ingredients market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.
Biotech APIs segment is expected to grow at the highest CAGR during the forecast period
On the basis of type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2019. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as growing demand of biotech drugs due to their specificity in action, advancements in biotechnology, increase in the demand for monoclonal antibodies and their similarity with the natural biological compounds found in the human body influence the growth of this segment.
Monoclonal antibodies segment is expected to account for the largest share of the global APIs market, by product type.
Based on product, the biotech APIs market is segmented into monoclonal antibodies, hormones, cytokines, fusion proteins, therapeutic enzymes, vaccines and blood factors. In 2019, the monoclonal antibodies segment is estimated to account for the largest share of the APIs market. A large share of monoclonal antibodies is due to their rising application in oncology and other therapeutic areas, increase in the number of FDA approvals for innovative biopharmaceutical products and increasing investments and technical advances in R&D for development of various novel products.
North America will dominate the market during the forecast period.
Geographically, the active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and rest of the World. In 2019, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and Asia. The major factors driving the overall growth of the APIs market in this region include the growing prevalence of preventable chronic diseases, increasing government emphasis on generic drugs, escalating demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Active Pharmaceutical Ingredients Market Overview
4.2 North America: Active Pharmaceutical Ingredients Market, by Type & Type of Manufacturer (2019
4.3 Active Pharmaceutical Ingredients Market: Geographic Growth Opportunities
5 Market Overview
5.2 Market Dynamics
18.104.22.168 Increasing Incidence of Chronic Diseases
22.214.171.124 Technological Advancements in Api Manufacturing
126.96.36.199 Growing Importance of Generics
188.8.131.52 Increasing Uptake of Biopharmaceuticals
184.108.40.206 Growing Adoption of Ai-Based Tools for Drug Discovery
220.127.116.11 Adoption of Organ-On-Chip Models in Drug Development
18.104.22.168 Focus on Precision Medicine
22.214.171.124 Investments in Real-World Evidence by Pharmaceutical Companies
126.96.36.199 Unfavorable Drug Price Control Policies
188.8.131.52 High Manufacturing Costs
184.108.40.206 Emerging Biosimilars Market
220.127.116.11 Highly Potent Active Pharmaceutical Ingredients
18.104.22.168 Emerging Markets
22.214.171.124 Emerging Technologies
126.96.36.199 Increasing Penetration of Counterfeit Drugs
5.3 Impact of COVID-19 on the Market
5.3.1 COVID-19 Drug R&D: Key Developments
5.3.2 COVID-19 Drug R&D: Vaccine Production Scenario, by Country
5.4 Value Chain Analysis
5.5 Supply Chain Analysis
5.6 Ecosystem Analysis of the Pharmaceuticals Market
6 Active Pharmaceutical Ingredients Market, by Type
6.2 Innovative Active Pharmaceutical Ingredients
6.2.1 Growing Number of New Molecular Entities Gaining Regulatory Approvals to Drive Market Growth
6.3 Generic Active Pharmaceutical Ingredients
6.3.1 Government Initiatives Supporting the Adoption of Generic Drugs to Boost Market Growth
7 Active Pharmaceutical Ingredients Market, by Type of Manufacturer
7.2 Captive Api Manufacturers
7.2.1 High Manufacturing Flexibility and Assurance of Product Quality are the Key Factors Supporting Market Growth
7.3 Merchant Api Manufacturers
7.3.1 Merchant Api Manufacturers Market, by Type
188.8.131.52 Innovative Api Manufacturers
184.108.40.206.1 Impending Patent Expiries and Increasing Costs of Innovative Drugs May Restrain the Market Growth
220.127.116.11 Generic Api Manufacturers
18.104.22.168.1 Low Manufacturing Cost of Generics Will Drive the Growth of this Segment
7.3.2 Merchant Api Manufacturers Market, by Type of Synthesis
22.214.171.124 Synthetic Api Manufacturers
126.96.36.199.1 Need for Specialized Manufacturing Capabilities is Driving the Growth of this Segment
188.8.131.52 Biotech Api Manufacturers
184.108.40.206.1 Complexity of Manufacturing Biotech Apis Has Increased the Focus on Partnerships Between Companies and Cmos
8 Active Pharmaceutical Ingredients Market, by Type of Synthesis
8.2 Synthetic Active Pharmaceutical Ingredients
8.2.1 Synthetic Active Pharmaceutical Ingredients Market, by Type
220.127.116.11 Innovative Synthetic Apis
18.104.22.168.1 High Value of Innovative Apis to Drive the Growth of this Segment
22.214.171.124 Generic Synthetic Apis
126.96.36.199.1 Initiatives to Promote the Penetration of Generics Will Drive the Growth of this Segment
8.3 Biotech Active Pharmaceutical Ingredients
8.3.1 Biotech Active Pharmaceutical Ingredients Market, by Type
188.8.131.52 Innovative Biotech Apis
184.108.40.206.1 Growing Demand for Innovative Biopharmaceuticals to Drive the Growth of this Segment
220.127.116.11 Generic Biotech Apis
18.104.22.168.1 Increasing Demand for Biosimilar Drugs due to Their Cost-Effectiveness to Drive the Growth of this Segment
8.3.2 Biotech Active Pharmaceutical Ingredients Market, by Product
22.214.171.124 Monoclonal Antibodies
126.96.36.199.1 Growing Applications of Antibody-Drug Conjugates in the Treatment of Cancer to Drive the Growth of this Segment
188.8.131.52 Hormones & Growth Factors
184.108.40.206.1 The Growing Incidence of Hormonal Disorders Will Drive Market Growth
220.127.116.11.1 Interferons and Interleukins Boost the Immune System and Have Important Applications in Cancer Treatment
18.104.22.168 Fusion Proteins
22.214.171.124.1 Growing Applications of Fusion Proteins in Biopharmaceuticals to Drive the Growth of this Segment
126.96.36.199 Recombinant Vaccines
188.8.131.52.1 Growing Prevalence of Infectious Diseases Has Boosted Vaccine Development-A Positive Indicator of Growth
184.108.40.206 Therapeutic Enzymes
220.127.116.11.1 Growing Significance of Enzymes in Therapies for Cancer and Pain Management Will Drive the Growth of this Segment
18.104.22.168 Blood Factors
22.214.171.124.1 Growing Incidence of Hemophilia to Drive the Growth of this Segment
8.3.3 Biotech Active Pharmaceutical Ingredients Market, by Expression System
126.96.36.199 Mammalian Expression Systems
188.8.131.52.1 Their Ability to Carry Post-Translational Modifications Will Drive the Market for These Systems
184.108.40.206 Microbial Expression Systems
220.127.116.11.1 These Systems Provide High Expression Levels of Proteins, Which Supports Their Use
18.104.22.168 Yeast Expression Systems
22.214.171.124.1 Advantages Such as Efficient Protein Secretion, Simple Purification, and Endotoxin-Free Products to Boost Demand
126.96.36.199 Insect Expression Systems
188.8.131.52.1 Efficient Post-Translational Modifications Provided by These Systems to Boost Their Demand
184.108.40.206 Other Expression Systems
9 Active Pharmaceutical Ingredients Market, by Type of Drug
9.2 Prescription Drugs
9.2.1 Growing Disease Prevalence is Expected to Drive the Prescription Drugs Market
9.3 Over-The-Counter Drugs
9.3.1 Sales of OTC Drugs Have Risen due to Innovations, Promotion of Self-Medication, and Increased Access
9.4 Active Pharmaceutical Ingredients Market, by Potency
9.4.1 Low-To-Moderate-Potency Active Pharmaceutical Ingredients
220.127.116.11 Higher Safety, Good Warning Properties, and Lack of Genic Effects Characterize Low-To-Moderate-Potency Apis
9.4.2 Potent-To-Highly Potent Active Pharmaceutical Ingredients
18.104.22.168 Most Drugs Under Development Fall into this Category
10 Active Pharmaceutical Ingredients Market, by Therapeutic Application
10.2 Communicable Diseases
10.2.1 Increasing Global Incidence of Communicable Diseases to Drive Market Growth
10.3.1 Increasing Spending on Cancer Medication to Support the Growth of this Segment
10.4.1 High Global Prevalence of Diabetes to Drive the Growth of this Segment
10.5 Cardiovascular Diseases
10.5.1 Growing Incidence of Cardiovascular Diseases Owing to Sedentary Lifestyles is a Major Growth Driver
10.6 Pain Management
10.6.1 Increasing Demand for Innovative and Advanced Pain Medications is a Major Growth Driver for this Market
10.7 Respiratory Diseases
10.7.1 High Global Prevalence of Respiratory Diseases to Drive the Growth of this Segment
10.8 Other Therapeutic Applications
11 Active Pharmaceutical Ingredients Market, by Region
11.2 North America
11.5 Rest of the World
12 Competitive Landscape
12.2 Market Evaluation Framework
12.3 Competitive Situation and Trends
13 Company Evaluation Matrix and Company Profiles
13.1 Company Evaluation Matrix Definition and Methodology
13.2 Company Evaluation Matrix
13.2.2 Emerging Leaders
13.2.3 Pervasive Players
13.2.4 Emerging Companies
13.3 Competitive Leadership Mapping - Start-Ups/Smes
13.3.1 Progressive Companies
13.3.2 Starting Blocks
13.3.3 Responsive Companies
13.3.4 Dynamic Companies
13.4 Market Player Ranking
13.5 Company Profiles
13.5.1 Pfizer, Inc.
13.5.2 Novartis Ag
13.5.4 Boehringer Ingelheim
13.5.5 Bristol-Myers Squibb
13.5.6 Teva Pharmaceutical Industries Ltd.
13.5.7 Eli Lilly and Company
13.5.8 GlaxoSmithKline plc
13.5.9 Merck & Co., Inc.
13.5.10 Mylan N.V.
13.5.11 Abbvie Inc.
13.5.12 F. Hoffmann-La Roche Ltd.
13.5.14 Dr. Reddy's Laboratories Ltd.
13.5.15 Sun Pharmaceutical Industries Ltd.
13.5.16 Cipla, Inc.
13.5.17 API Pharma Tech
13.5.18 BDR Pharmaceuticals International Pvt. Ltd.
13.5.19 Sreepathi Pharmaceuticals Limited
13.5.20 Shilpa Medicare Limited
For more information about this report visit https://www.researchandmarkets.com/r/8ht1cg
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900